Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

Jing Zhang; Yan Gu; Baoan Chen

doi:10.2147/CMAR.S400013

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

Cancer Manag Res. 2023 Feb 25:15:245-255. doi: 10.2147/CMAR.S400013. eCollection 2023.

Authors

Jing Zhang¹, Yan Gu¹, Baoan Chen¹

Affiliation

¹ Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People's Republic of China.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed that drug resistance is the main cause of the recurrence and refractory of DLBCL (R/R DLBCL). With the increased understanding of DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab have been used for R/R DLBCL. This article will review the drug resistance mechanism and novel targeted drugs and therapies of DLBCL.

Keywords: CAR-T therapy; CD47; NF-κB; antibody drug-conjugate; drug resistance; relapse and refractory DLBCL; targeted therapy.

Publication types

Review